Pfizer ($PFE) fell short in the first of three Phase III studies to test a new and long-acting formulation of its drug Lyrica as an anti-seizure remedy for patients with epilepsy, the U.S. drug giant revealed on Friday. The study, which tested the formulation as a once-a-day therapy, missed its main goal of changing seizure frequency compared with placebo. Article